Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
28. (WO2009092002) ANTIRETROVIRAL DRUG FORMULATIONS FOR TREATMENT OF CHILDREN EXPOSED TO HIV/AIDS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

We claim:

1. A rapidly dissolving pharmaceutical formulation to reduce the incidence of mother to child transmission of human immunodeficiency virus comprising:
a therapeutically effective amount of an active medicament selected from zidovudine and nevirapine; and
a non-active ingredients matrix comprising:
one or more excipient comprising from 15% to 95% by weight of the total
formulation;
one or more superdisintegrant comprising from 1% to 8% by weight of the
total formulation;
one or more sweeteners comprising from 0.1% to 11% by weight of the total
formulation; and
one or more lubricants comprising from 0.1% to 3% by weight of the total
formulation;
wherein the formulation substantially dissolves in an aqueous solution in less than 60 seconds.

2. The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is a rapidly dissolving granule formulation and the non-active ingredients matrix comprises:
one or more excipient comprising from 50% to 95% by weight of the total
granule formulation;
one or more superdisintegrant comprising from 1% to 4% by weight of the
total granule formulation;
one or more sweeteners comprising from 0.1% to 5% by weight of the total
granule formulation; and
one or more lubricants comprising from 0.1% to 3% by weight of the total
granule formulation,
wherein the granule formulation substantially dissolves in an aqueous solution in less than 40 seconds.

3. The pharmaceutical formulation of claim 2, wherein the therapeutically effective amount of the active medicament is zidovudine in from 4% to 30% by weight of the total granule formulation.

4. The pharmaceutical formulation of claim 1, wherein the therapeutically effective amount of the active medicament is nevirapine in from 2% to 25% by weight of the total granule formulation.

5. The pharmaceutical formulation of any of claims 2-4, wherein the one or more sweeteners are selected from the group consisting of saccharin, sucralose, xylitol, sucrose, aspartame, cyclamate, acesulfame potassium, and combinations of any thereof.

6. The pharmaceutical formulation of any of claims 2-5, wherein the granules have a geometric mean diameter ranging from 50 microns to 150 microns

7. The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is a rapidly dissolving tablet formulation and the non-active ingredients matrix comprises:
one or more excipient comprising from 15% to 75% by weight of the total
tablet formulation;
one or more superdisintegrant comprising from 1.5% to 8% by weight of the
total tablet formulation;
one or more sweeteners comprising from 2% to 11% by weight of the total
tablet formulation; and
one or more lubricants comprising from 0.5% to 3% by weight of the total
tablet formulation.

8. The pharmaceutical formulation of claim 7, wherein the therapeutically effective amount of the active medicament is zidovudine in from 5% to 30% by weight of the total tablet formulation.

9. The pharmaceutical formulation of claim 7, wherein the therapeutically effective amount of the active medicament is nevirapine in from 5% to 25% by weight of the total tablet formulation.

10. The pharmaceutical formulation of any of claims 7-9, wherein the one or more sweeteners are selected from the group consisting of from 1.5% to 6% by weight of xylitol, from 0.75% to 5% by weight of sucralose, and combinations thereof.

11. The pharmaceutical formulation of any of claims 1-10, wherein the one or more superdisintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crosslinked polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymer, and combinations of any thereof.

12. The pharmaceutical formulation of any of claims 1-11, wherein the one or more lubricants is selected from the group consisting of magnesium stearate, talc, fumed silica, and combinations of any thereof.

13. The use of a pharmaceutical formulation comprising: a therapeutically effective amount of an active medicament selected from zidovudine and nevirapine; and a non-active ingredients matrix comprising:
one or more excipient comprising from 15% to 95% by weight of the total formulation; one or more superdisintegrant comprising from 1% to 8% by weight of the total
formulation;
one or more sweeteners comprising from 0.1% to 11% by weight of the total
formulation; and
one or more lubricants comprising from 0.1% to 3% by weight of the total formulation, in the manufacture of a rapidly dissolving formulation for reducing the incidence of mother to child transmission of human immunodeficiency virus.

14. The use of the formulation of claim 13, wherein the formulation is a rapidly dissolving granule formulation and the non-active ingredients matrix comprises:
one or more excipient comprising from 50% to 95% by weight of the total
granule formulation;
one or more superdisintegrant comprising from 1% to 4% by weight of the
total granule formulation;
one or more sweeteners comprising from 0.1% to 5% by weight of the total
granule formulation; and one or more lubricants comprising from 0.1% to 3% by weight of the total
granule formulation,
wherein the granule formulation substantially dissolves in an aqueous solution in less than 40 seconds.

15. The use of the formulation of claim 13 , wherein the therapeutically effective amount of the active medicament is zidovudine in from 4% to 30% by weight of the total granule formulation.

16. The use of the formulation of claim 13, wherein the therapeutically effective amount of the active medicament is nevirapine in from 2% to 25% by weight of the total granule formulation.

17. The use of the formulation of any of claims 13-16, wherein the formulation is administered to a patient ranging from 0 to 18 months of age.

18. The use of the formulation of claim 13, wherein the formulation is a rapidly dissolving tablet formulation and the non-active ingredients matrix comprises:
one or more excipient comprising from 15% to 95% by weight of the total
tablet formulation;
one or more superdisintegrant comprising from 1% to 8% by weight of the
total tablet formulation;
one or more sweeteners comprising from 0.1% to 11% by weight of the total
tablet formulation; and
one or more lubricants comprising from 0.1% to 3% by weight of the total
tablet formulation.

19. The use of the formulation of claim 18, wherein the therapeutically effective amount of the active medicament is zidovudine in from 5% to 30% by weight of the total tablet formulation.

20. The use of the formulation of claim 18, wherein the therapeutically effective amount of the active medicament is nevirapine in from 5% to 25% by weight of the total granule formulation.

21. The use of the formulation of any of claims 18-20, wherein the formulation is administered to a patient ranging from 6 months to 18 months in age.

22. A rapidly dissolving pharmaceutical formulation for the treatment of HI V/ AIDS in children comprising:
lamivudine in from 0.4% to 10% by weight of the total formulation;
zidovudine in from 0.65% to 25% by weight of the total formulation; and
a non-active ingredients matrix comprising:
one or more excipient comprising from 1.0% to 55% by weight of the total
formulation;
one or more superdisintegrant comprising from 0 % to 8% by weight of the
total formulation;
one or more sweeteners comprising from 0.75% to 92.52% by weight of the total
formulation;
one or more flavorants comprising from 0% to 0.20% by weight of the total
formulation;
one or more lubricants comprising from 0 % to 3% by weight of the total
formulation; and
one or more parabens preservative comprising from 0% to 0.44% by weight of
the total formulation,
wherein the formulation is in the form of a tablet or granules and substantially dissolves or forms a suspension in an aqueous solution in less than 60 seconds.

23. The pharmaceutical formulation of claim 22, wherein the formulation is in the form of a rapidly dissolving tablet ranging from about 200 mg to about 400 mg in weight.

24. The pharmaceutical formulation of claim 22 or 23, wherein the zidovudine comprises from 4.5% to 25% by weight of the total tablet formulation, the lamivudine comprises from 2.2% to 10% by weight of the total tablet formulation, the one or more excipient comprise from 12% to 55% by weight of the total tablet formulation, the one or more superdisintegrant comprise from 1.5% to 8% by weight of the total tablet formulation, the one or more sweeteners comprise from 0.75% to 12% by weight of the total tablet formulation, and the one or more lubricants comprising from 0.5% to 3% by weight of the total tablet formulation.

25. The pharmaceutical formulation of any of claims 22-24, further comprising nevirapine in from 4% to 20% by weight of the total tablet formulation.

26. The pharmaceutical formulation of any of claims 22-25, wherein the one or more sweeteners comprise xylitol in from 1.5% to 6% by weight of the total formulation and sucralose in from 0.75% to 6% by weight of the total formulation and wherein the one or more flavorants are selected from the group consisting of cherry flavorants, grape flavorants, raspberry, bubble gum, and mixed fruit flavorants.

27. The pharmaceutical formulation of claim 22, wherein the formulation is in the form of rapidly dissolving reconstitutable granules having a geometric mean diameter ranging from 200 microns to 400 microns.

28. The pharmaceutical formulation of claim 22 or 27, wherein the zidovudine comprises from 0.65% to 6.5% by weight of the total granule formulation, the lamivudine comprises from 0.4% to 2.65% by weight of the total granule formulation, the one or more excipient comprises a suspending agent in from 1.0% to 5.4% by weight of the total granule formulation, the one or more sweetener comprises xylitol in from 25% to 92% by weight and sucralose in from 0.08% to 0.52% by weight of the total granule formulation, the one or more flavorants comprising from 0.0001% to 0.20% by weight of the total formulation, and the one or more parabens preservative comprises methyl paraben in from 0.075% to 0.40% by weight and propyl paraben in from 0.008% to 0.038% by weight of the total granule formulation.

29. The pharmaceutical formulation of any of claims 22 and 27-28, further comprising nevirapine in from 0.5% to 2.7% by weight of the total granule formulation.

30. A reconstitutable stable aqueous suspension of the rapidly dissolving pharmaceutical formulation of any of claims 22-29.

31. The use of a pharmaceutical formulation comprising:
lamivudine in from 0.4% to 10% by weight of the total formulation;
zidovudine in from 0.65% to 25% by weight of the total formulation; and
a non-active ingredients matrix comprising: one or more excipient comprising from 1.0% to 55% by weight of the total
formulation;
one or more superdisintegrant comprising from 0% to 8% by weight of the
total formulation;
one or more sweeteners comprising from 0.75% to 92.52% by weight of the total
formulation;
one or more flavorants comprising from 0% to 0.20% by weight of the total
formulation;
one or more lubricants comprising from 0 % to 3% by weight of the total
formulation; and
one or more parabens preservative comprising from 0% to 0.44% by weight of the
total formulation,
wherein the formulation is in the form of a tablet or granules and substantially dissolves or forms a suspension in an aqueous solution in less than 60 seconds,
in the manufacture of a rapidly dissolving formulation for the treatment of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) in children.

32. The use of the pharmaceutical formulation of claim 31 , wherein the formulation further comprises nevirapine in from 0.5% to 20% by weight of the total formulation.

33. The use of the pharmaceutical formulation of any of claims 31-32, wherein the pharmaceutical formulation is administered to a patient ranging from 3 months to 16 years of age.

34. The use of the pharmaceutical formulation of any of claims 31-33, wherein the pharmaceutical formulation is administered orally to a patient in the form of a tablet or a reconstituted aqueous suspension.